Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00412984 · ClinicalTrials.gov registry record · Phase 3
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
A Phase 3 study of Atrial Fibrillation and Atrial Flutter, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 20,976
- Enrollment target
- 20
- Study locations
NCT00412984 is a Phase 3 study of Atrial Fibrillation and Atrial Flutter that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 20,976 participants, above the 2,893-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (625% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT00412984, a Phase 3 study of Atrial Fibrillation and Atrial Flutter, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20,976 participants
- Enrollment target
- 20
- Study locations
Study Summary
The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.
Conditions Studied
Interventions
- DRUG warfarin
- DRUG apixaban
Study Locations (20)
California
- Advanced Clinical Reserach Institute - Anaheim
- Act/Cardiovascular Research Institute - Beverly Hills
- Capitol Interventional Cardiology - Carmichael
- Escondido Cardiology Associates, Inc. - Escondido
- William D. Bowden, D.O. - Healdsburg
- La Mesa Cardiac Center, A Medical Group - La Mesa
- Va Greater Los Angeles Healthcare System - Los Angeles
Alabama
- Cardiovascular Associates, Pc - Birmingham
- Alabama Internal Medicine Pc - Birmingham
- Birmingham Heart Clinic P.C. - Birmingham
- Heart Center, Inc. - Huntsville
- Mobile Heart Specialists, Pc - Mobile
- Clara V. Massey, Md - Mobile
Arizona
- Internal Medicine Physicians Associates, P.C. - Phoenix
- Southwest Heart - Tucson
- Southern Arizona Va Health Care System - Tucson
- Pima Research Foundation - Tucson
Arkansas
- Dr. Rajesh Shroff - Hot Springs
- Mary K. Richards, Md Pa - Little Rock
Alaska
- Alaska Heart Institute - Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,976 participants |
| Start Date | 2006-12-31 |
| Est. Completion | 2011-05-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00412984
The ClinicalTrials.gov registry entry for NCT00412984 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20,976 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,893-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (625% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which warfarin is the first listed.
NCT00412984 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00412984 about?
NCT00412984 is a clinical study titled "Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation". The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.
What is the current status of trial NCT00412984?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20,976 participants. The study started on 2006-12-31. Estimated completion is 2011-05-25.
What conditions does trial NCT00412984 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Atrial Flutter.
What interventions are being tested in trial NCT00412984?
The interventions under investigation include: warfarin (DRUG), apixaban (DRUG).
Who is sponsoring clinical trial NCT00412984?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00412984 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
RECRUITING · Phase 3
-
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
RECRUITING · Phase 3
-
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
RECRUITING · Phase 3
-
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.